Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Study of CC-486 (Oral Azacitidine) in Hematological Disorders
NCT02494258Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2015
- Primary completion
- Apr 2025
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 2
01
Overview
A Phase 2 trial of CC-486 in hematological malignancies, sponsored by Celgene Corporation. Started Oct 2015; status: completed.
02
Drugs
CC-486
03
Conditions
hematological malignancies
Beyond the preview
Go deeper on NCT02494258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02494258.